RAD51 and neoplasm: Consistent with the result of in vitro experiment, the PDX model tumor burden of three treatment groups illustrated that when combined with miR-509-3, Olaparib was more effective in reducing tumor burden in two PDX cases (PDX1 and PDX9) along with the decline in RAD51 positive rate.